Published in Org Lett on September 14, 2006
Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol (2008) 1.37
Organic chemistry and biology: chemical biology through the eyes of collaboration. J Org Chem (2009) 1.05
Asymmetric Eschenmoser-Claisen rearrangement for anti-beta-substituted gamma,delta-unsaturated amino acids. Org Lett (2007) 0.94
Enantioselective synthesis of anti-beta-substituted gamma,delta-unsaturated amino acids: a highly selective asymmetric thio-Claisen rearrangement. Org Lett (2008) 0.80
A density functional theory approach toward substituent effect in Meerwein-Eschenmoser-Claisen rearrangement. J Mol Model (2011) 0.75
Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers (1997) 1.69
Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues. Biopolymers (2005) 1.54
Asymmetric chelated Claisen rearrangements in the presence of chiral ligands--scope and limitations. Chemistry (2002) 1.31
Application of the Ester Enolate Claisen Rearrangement in the Synthesis of Amino Acids Containing Quaternary Carbon Centers. J Org Chem (1996) 1.07
Rational Molecular Design and EPC Synthesis of a Type VI beta-Turn Inducing Peptide Mimetic This work was supported by the BMBF and the Fonds der Chemischen Industrie. EPC=enantiomerically pure compound. Angew Chem Int Ed Engl (2001) 1.06
Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr Med Chem (2000) 1.01
Stereoselective Backbone Modifications of Peptides via Chelate Enolate Claisen Rearrangement. J Org Chem (1999) 0.98
Spirolactams as conformationally restricted pseudopeptides: synthesis and conformational analysis. J Org Chem (2002) 0.87
C2-symmetrical tetrahydroxyazepanes as inhibitors of glycosidases and HIV/FIV proteases. Bioorg Med Chem (1996) 0.85
Tuning the strain and polymerizability of organometallic rings: the synthesis, structure, and ring-opening polymerization behavior of [2]ferrocenophanes with C-SI, C-P, and C-S bridges. J Am Chem Soc (2001) 0.83
Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature (2010) 6.26
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell (2002) 3.21
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci (2005) 2.61
MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem (2010) 2.49
The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A (2003) 2.29
Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol (2011) 2.24
Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res (2004) 2.13
No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat (2010) 2.12
Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet (2011) 2.05
Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet (2012) 2.00
Antinociceptive and nociceptive actions of opioids. J Neurobiol (2004) 1.93
Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets (2004) 1.86
Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene (2004) 1.77
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology (2005) 1.67
Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions. Anal Biochem (2004) 1.66
S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One (2011) 1.63
Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg Med Chem Lett (2004) 1.58
The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res (2005) 1.56
Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues. Biopolymers (2005) 1.54
Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain (2005) 1.49
Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer (2011) 1.46
Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects. Breast Cancer Res Treat (2010) 1.43
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem (2006) 1.40
A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China. J Gen Virol (2005) 1.38
Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol (2008) 1.37
Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36
A robust and accurate binning algorithm for metagenomic sequences with arbitrary species abundance ratio. Bioinformatics (2011) 1.34
Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31
Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg Med Chem (2009) 1.28
Development of a lanthanide-based assay for detection of receptor-ligand interactions at the delta-opioid receptor. Anal Biochem (2005) 1.25
Rhodopsin reconstituted into a planar-supported lipid bilayer retains photoactivity after cross-linking polymerization of lipid monomers. J Am Chem Soc (2005) 1.24
Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett (2006) 1.23
Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem (2007) 1.21
Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem (2007) 1.21
Enhanced targeting with heterobivalent ligands. Mol Cancer Ther (2009) 1.21
Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J Am Chem Soc (2010) 1.20
Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res (2006) 1.19
Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets (2003) 1.19
Rigid linkers for bioactive peptides. Bioconjug Chem (2006) 1.19
Blockade of melanocortin transmission inhibits cocaine reward. Eur J Neurosci (2005) 1.17
Phosphatidylethanolamine enhances rhodopsin photoactivation and transducin binding in a solid supported lipid bilayer as determined using plasmon-waveguide resonance spectroscopy. Biophys J (2004) 1.17
Ultrafast protein splicing is common among cyanobacterial split inteins: implications for protein engineering. J Am Chem Soc (2012) 1.16
Novel 3D pharmacophore of alpha-MSH/gamma-MSH hybrids leads to selective human MC1R and MC3R analogues. J Med Chem (2005) 1.16
Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem (2006) 1.16
Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria. Mol Cell Biol (2005) 1.16
Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Cancer Res (2009) 1.16
Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors. Bioorg Med Chem Lett (2007) 1.15
Solution structures of cyclic melanocortin agonists and antagonists by NMR. Biopolymers (2003) 1.14
Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain (2008) 1.13
Direct observation of G-protein binding to the human delta-opioid receptor using plasmon-waveguide resonance spectroscopy. J Biol Chem (2003) 1.11
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther (2007) 1.11
Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment. J Med Chem (2011) 1.10
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. J Med Chem (2002) 1.09
Sex-specific mediation of opioid-induced hyperalgesia by the melanocortin-1 receptor. Anesthesiology (2010) 1.08
Development of potent μ and δ opioid agonists with high lipophilicity. J Med Chem (2010) 1.08
Converging protein kinase pathways mediate adenylyl cyclase superactivation upon chronic delta-opioid agonist treatment. J Pharmacol Exp Ther (2003) 1.08
A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists. J Med Chem (2008) 1.08
The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer (2003) 1.06
Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol (2004) 1.06
The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. Bioorg Med Chem (2009) 1.05
Involvement of S100A14 protein in cell invasion by affecting expression and function of matrix metalloproteinase (MMP)-2 via p53-dependent transcriptional regulation. J Biol Chem (2012) 1.05
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res (2014) 1.05
Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem (2006) 1.05
Stereoselective synthesis of novel dipeptide beta-turn mimetics targeting melanocortin peptide receptors. Org Lett (2003) 1.05
Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin /TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer (2005) 1.04
Design of cyclic and other templates for potent and selective peptide alpha-MSH analogues. Curr Opin Chem Biol (2005) 1.04
Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord. J Am Chem Soc (2014) 1.03
Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers. J Am Chem Soc (2005) 1.03
Selectivity, cooperativity, and reciprocity in the interactions between the delta-opioid receptor, its ligands, and G-proteins. J Biol Chem (2004) 1.03
Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. J Pharmacol Exp Ther (2004) 1.03
Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors. Int J Pept Res Ther (2008) 1.02
The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists. J Med Chem (2008) 1.02
Stereoselective synthesis of dipeptide beta-turn mimetics: 7-benzyl and 8-phenyl substituted azabicyclo[4.3.0]nonane amino acid esters. J Org Chem (2002) 1.02
Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin Cancer Res (2005) 1.02
Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol (2007) 1.01
B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J Biol Chem (2005) 1.01
Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists. J Med Chem (2009) 1.00
RIM promotes calcium channel accumulation at active zones of the Drosophila neuromuscular junction. J Neurosci (2012) 1.00
Peptide-labeled quantum dots for imaging GPCRs in whole cells and as single molecules. Bioconjug Chem (2007) 1.00
Cell-specific targeting by heterobivalent ligands. Bioconjug Chem (2011) 1.00
Reduced MTA1 expression by RNAi inhibits in vitro invasion and migration of esophageal squamous cell carcinoma cell line. Clin Exp Metastasis (2006) 1.00
Streamlined expressed protein ligation using split inteins. J Am Chem Soc (2012) 0.99
Antidiabetic and antioxidant effects of oleanolic acid from Ligustrum lucidum Ait in alloxan-induced diabetic rats. Phytother Res (2009) 0.99
Lipid bilayers on polyacrylamide brushes for inclusion of membrane proteins. Langmuir (2005) 0.99
Design, synthesis, and validation of a branched flexible linker for bioactive peptides. J Org Chem (2007) 0.98
High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol (2007) 0.98
Ligand modulation of lateral segregation of a G-protein-coupled receptor into lipid microdomains in sphingomyelin/phosphatidylcholine solid-supported bilayers. Biochemistry (2005) 0.98
Techniques: plasmon-waveguide resonance (PWR) spectroscopy as a tool to study ligand-GPCR interactions. Trends Pharmacol Sci (2003) 0.97
Stereoselective bromination-suzuki cross-coupling of dehydroamino acids to form novel reverse-turn peptidomimetics: substituted unsaturated and saturated indolizidinone amino acids. Org Lett (2002) 0.97
Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem (2007) 0.96
Structure-activity relationships of novel cyclic alpha-MSH/beta-MSH hybrid analogues that lead to potent and selective ligands for the human MC3R and human MC5R. J Med Chem (2003) 0.96
A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway. Biochem J (2009) 0.96
Comparing fuel reduction treatments for reducing wildfire size and intensity in a boreal forest landscape of northeastern China. Sci Total Environ (2013) 0.96
Real time differentiation of G-protein coupled receptor (GPCR) agonist and antagonist by two photon fluorescence laser microscopy. J Am Chem Soc (2004) 0.95
Different structural states of the proteolipid membrane are produced by ligand binding to the human delta-opioid receptor as shown by plasmon-waveguide resonance spectroscopy. Mol Pharmacol (2004) 0.95
[N-({(R)-2-[(N-Benzylprolyl)amino]phenyl}-phenylmethylene)-2(S)-(pent-4-enyl)-glycinato]nickel(II). Acta Crystallogr Sect E Struct Rep Online (2006) 0.95